bluebird bio Inc (LTS:0HOH)
$ 0.3637 0 (0%) Market Cap: 73.46 Mil Enterprise Value: 371.21 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

bluebird bio Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean - PLENARY SESSION: COMMERCIAL STRATEGIES FROM PATHFINDERS IN THE INDUSTRY Transcript

Apr 23, 2019 / 07:45AM GMT
Release Date Price: $161.11
Matthew Durdy
Catapult Genetics Pty. Ltd. - Chief Business Officer& Director

Good morning. My name is Matthew Durdy. I'm the Chief Business Officer of the Cell and Gene Therapy Catapult. And we now have a panel presentation on commercialization.

Is that Dan? Sure. Sit here. Have you got a mic on? There's a microphone just coming for you then.

A couple of years ago, or quite a few years ago now, when we set off with the Cell and Gene Therapy Catapult with a mission to try and help the industry industrialize and create growth, we used to go and talk to people who are developing therapeutics and say, "You need to think about adoption. You need to think about pricing and reimbursement." And they'd look at us and go, "Yes, that's right, that's great." But what we're really concerned about is whether or not we're going to get a hearing with the regulator, whether or not the regulator is going to talk to us seriously. So it's fantastic to hear a presentation like we just heard, where ATMP is a part of the mainstream and part of adoption. It's also fantastic to hear in that presentation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot